Today. This is all about this guy. Bob, what was happening in this photo?
See, I guess I was, I think that was somebody taking a picture of me in the lab.
Yeah. So, this is really your lab. It's not a movie set.
No, no, it's the lab. Yeah, but they had, they're trying to be artistic.
Yeah. How about this one? Same lab?
Yeah. How about these, your books or you rented these books?
Uh, actually that part looks fine. The only reason it looks funny is my office isn't that organized, but...
So I'm just going through a few. Yeah, you're proud to be on the Globe probably.
Well, not with that title, but...
Not with that. Oh, I didn't read it. Yeah, we went fast. So Bob is a special guy. Apparently he has 44 honorary degrees. You know, if you do the math, that's like a year, two years of your life having to travel around the world. Like when you get called to get an honorary degree, do you cringe because it's like a day and a half or are you excited?
It may depend where it is.
Yeah. And then, you know, just Bob is amazing. Here he is with George Bush, Obama, the Queen of England. He's gotten a lot of prizes there. He's with Bill Gates. I emailed my friend Erling Norby and he's one of five people for 22 years decided who got the Nobel prizes. He's a physiologist and I said to him, you know, Bob's got 220 major awards. He didn't get the Nobel. What's going on? And he said, Bob has a fantastic career which he can describe vividly. The walls of his office are overcrowded with recognition of his achievement. I said, you didn't answer my question. What about the Nobel? And he says, John, all information on candidates for Nobel prizes remain secret for 50 years. Hence, my lips are sealed. What I can say is that the prize in chemistry can be given for a discovery of an invention. So, I don't know how to interpret that, but you may be in the mix. I don't know, but I'm sure you're not holding out. You're doing just fine. So, what is this? Is this fake news or did this really happen?
Oh, no. That was definitely, yeah, that's real.
Yeah. So, that's Bill Gates. Did you go to him or he come to you?
Well, that picture he came to me, but I certainly go out to him a number of times. I give him a lecture every year for several hours, but he's been great. You know, they've been very supportive of our lab.
Yeah. And one of the first times he came, you know, I know this is a little out of order, but why did he come? What was he excited to talk to you about or challenge you to help solve?
Well, a bunch of things. You know, it was 2012 and I had met him before because he helped Nathan Myhrvold with his Intellectual Ventures. And I remember one day we had a session on inventing and I guess he was talking to Lowell Wood, who actually is one of the top inventors in the world, and he was talking about issues like could we do better vaccines, could we do better nutrition. And Lowell said, well, he should come and see me. So he did. So that was, you know, 13 years ago and we've actually worked very closely ever since. And not just him, but the foundation's been wonderful and they've been supportive of different companies I've been involved with and have helped start. And they were just there in August and he's always been super helpful.
Great. There's another, these are some of those awards. That's not Photoshop, right? Those are real.
No, no, none of the, yeah, those are...
Yeah. So this I just found on the web. You know, what are we looking at here?
Different products that have been based in part on things that we've done.
And what does this range say? Like, I don't think...
I have to look. So it's...
You're not a one-trick pony here.
Yeah. Well, it's like we've had a lot of great people working in the lab and a lot of great companies, but they started from... but you know, there are all kinds of treatments for cancer, eye diseases. I think this is, I have to lean back, I think this is actually aquaculture, which is, Yanni Zohar who did a lot of work with us developed, I mean, which is now this huge industry. I didn't even realize it. In fact, Dan, I remember, I don't know if you went to his talk back at that 70th thing, he said it's a quarter of a trillion dollar industry. But so he's developed a lot of different implants.
So, let me, I'm going to give a little more formal background on Bob. He's an economic force, GDP of a small country. You know, we don't have the headquarters of Meta or Microsoft here, but we have Bob Langer. Ultimate inventor and medical science translator. He's one of the most prolific inventors, biotech entrepreneur of our time. His contributions include spanning drug delivery, tissue engineering, nanotechnology, and entrepreneurship. He has challenged conventional wisdom in his field. Grew up in Albany.
And your dad lived through the Great Depression and World War II.
Well, he lived through the Great Depression and he fought in World War II. He was a navigator.
Yeah. And he ran a liquor store in Albany.
Yeah. Billiards parlor in Troy and a liquor store in Albany.
Yeah. And he came home and played math games with you growing up.
How did your dad kind of shape you and your sister and your mom? Just think of those early days. I know you had erector sets and chemistry sets and microscopes and you had a small lab in your basement. But when you think back to your origins, those early days.
Well, I lived on, you know, we had this house in Tudor Road and, you know, a couple bedrooms, but it was a great neighborhood. You know, I'd play sports a lot, you know, baseball and football and stuff like that. But in terms of what you're asking of my dad, I mean, he and my mom, they'd get me these presents. And some of those presents, you know, were regular things. But they did get, there was a, if you're old enough, they had these sets called Gilbert sets, and they made an erector set that you could make a rocket launcher and robots and a parachute jump. They had the microscope set, and you could watch shrimp eggs hatch. And they had a chemistry set, which you could mix things together and I don't want to say blow things up, but you could make colors change. I always liked magic and make rubber and different things like that. So that is what I set up in our little basement.
Yeah. Early days. And then you went west. You went to Cornell.
I guess that's west. You know, it's funny. I had never been actually west of Buffalo, I think, till I was 25 years old. Yeah. But that was west for me.
Yeah. And you studied chemistry. I think in retrospect, you said you were never tested for attention deficit, but maybe, you know, that was a superpower or something that you had going on.
I don't know if I looked at it as a superpower. I thought there was something wrong with me. Yeah. You know, it's like I just tried to pay attention in class. They didn't know. I mean, they didn't have that term then. So, you know, I tried to pay attention in class and I would just daydream a lot.
Yeah, and so it was hard. And there were a number of classes like English and French that I did very badly in, and I just had trouble paying attention.
So then you got into a PhD program at MIT and in reading a little bit about your background, you taught some high school kids. There was like an alternative high school that was set up and you had a lot of fun teaching there, hands-on learning, making ice cream, making rubber. How did that shape early Bob Langer?
So what happened was when I was an undergraduate at Cornell, I was a teaching assistant. I really liked that and I came up to Boston actually in 1970 to start graduate school at MIT and I was looking for some way to do things like that and I did some tutoring in Roxbury and also in Cambridge. So a group of people were starting a school, an alternative high school in Cambridge in 1970, which they'd call the Group School. And they asked me if I would help on math and science. And actually, it was an amazing thing what they did. I mean, so I don't know if people think back to what it was like here in 1970. You know, Cambridge actually, even though it's got Harvard and MIT, had the highest high school dropout rate in the country and, you know, there were all these projects like Jefferson Park and Roosevelt Towers. So anyhow, we started the school and the students had a major part of governance, but also Cambridge was pretty liberal. I mean, it's pretty liberal now, but it was very liberal then. And so it was like you didn't have to take math, you didn't have to take really anything that you didn't want to, but I tried to make it fun and tried to make it relevant. And I still remember what I was very proud of, the first year I think five kids out of 37 signed up for math, but the second year 45 out of 50 did. And so...
Yeah, well, they seemed to like it. And then chemistry, we created a more, you know, kind of a chemistry program with MIT gave us some funding. And I think, you know, that was it, to do some useful, you know, you come up with practical ways of making chemistry useful, like making polymers, even making ice cream, which I'm always fond of, which illustrates what's called freezing point lowering. And so that, but anyhow, what happened, and I also actually, interestingly enough, I got very involved in helping one of the biggest problems when you start an alternative high school for people that don't have any money, it was for, you know, working-class kids, is that I got involved in fundraising and, you know, we'd write, I'd help people to write grants and we did raise a reasonable amount of money. So what effect did that have on me later? Well, you know, if you're a professor, you spend a lot of time raising money and it's not very easy, but however hard that is, it was a lot harder doing it with the school. So I think that really shaped one of the things I did. And secondly, I mean, I really loved doing the teaching. And so I think that's part of what happened is a lot of my classmates when I graduated, they wanted to work for oil companies. They paid a lot of money and I interviewed at those places.
So let me double down on that. I wanted to highlight, you know, this is a guy who has a 100-person lab and has taught so many, and there are legions of people out there that are disciples of Bob Langer. And, you know, maybe that high school experience was seminal in helping to shape you. In terms of '74, you graduate, you got 20 job offers from big oil. You know, you had credentials to go help the oil industry. You write about flying down to Louisiana where an Exxon engineer said that if you increased chemical yield by 0.1%, it would be worth billions, and then you were flying home. What were you thinking at that point? And I know you had gotten four Exxon offers around that time. But, you know, did you go into the oil industry like a lot of other chemical engineers? And what choice did you make at that point?
Yeah, when I flew back that night thinking about making such a tiny increase, I just thought to myself, I didn't want to spend my life doing that. Yeah, and so I didn't. I really wasn't sure what I was going to do because that's, you know, almost everybody then worked in chemical engineering, worked in the chemical industry, mostly the oil industry. So mostly I just thought, you know, worse came to worse, I'd look for other things and I tried to think about things, but worse came to worse, I'd maybe work in an ice cream parlor for a year or two because I...
Yeah. So, you probably recognize this chart. Yeah. I know you applied to Cooney to be a teacher, they didn't get back to you. Applied to 40 other schools, no one got back to you, but then someone in your group said, "Hey, there's this surgeon who sometimes hires unusual people." So, maybe fill in, you know, what happened at that point.
So, yeah. So what happened is I did start seeing ads to do curriculum development like I did at the City College of New York, which you mentioned was the first one, but they didn't write me back, nor did a lot of others once I had that idea.
But you have honorary degrees from some of those 40. But that's another thing.
Well, actually, they weren't very good schools. They still didn't even write me back.
But I think the honorary degrees I have are from pretty good places, like Oxford and Harvard, Yale and others. But anyhow, those places, I didn't write them. I mean, they didn't have those kinds of jobs.
But, you know, so what happened was, you know, one day I was walking in the lab. Well, I also wrote a lot of hospitals and after that the next idea was working in like a hospital or medical school. So I wrote a lot of those places who didn't write me back either and I was getting very good at things like... but so when I was walking in the lab one day, one of the older scientists, Barry Bunau, who was actually an MD, he said to me, Bobby, he said, there's a surgeon in Boston named Judah Folkman and he sometimes hires unusual people. Dr. Folkman. I had not heard of him, but he was a very famous young surgeon, actually the youngest full professor in the history of Harvard Medical School. And so he called me up and said, well, would I like to come over for an interview?
And so you worked, what's going on in this chart? Is this, had you started working with him at this point?
I did, but for, I don't know if anybody remembers or knows what Dr. Folkman, you'd probably have to be older to know. But Dr. Folkman had this idea that if you could stop blood vessels, you could stop cancer. It was a really very revolutionary idea and that most people didn't really believe in. And he was widely criticized for it, but he wouldn't give up. And his idea in particular was that the thing that caused blood vessels to grow was a substance like a protein that would diffuse out and be a signal to those blood vessels. So that was his theory, but of course it wasn't proven. So he hired me to do two things, I guess. One, prove he was right, but two, in so doing, isolate the first substances that could stop blood vessels from growing. It was actually a pretty hard thing to do because there's no way to study blood at that time. There's no real way to study blood vessels. So we had to invent one. And the difficulty is there's always background blood vessels most places, but there's a few places where there aren't: the chorioallantoic membrane of a chicken and corneas. And so our idea was we'd put a tumor in those, which would cause blood vessels to grow. But then we needed a tiny little particle next to it, like a micro or nanoparticle that could deliver these large molecules like proteins or DNA. And that hadn't been done before. And he was advisor to the one company in the world, Alza, at that time, that was working on anything even close to that. And they had like Nobel Prize winners and people like that on their board. They all said that was impossible. But if we were going to solve the blood vessel problem, we had to solve the delivery problem. So that graph that you showed came from a paper we wrote in Nature in 1976, the Journal of Nature, that showed for the first time you could release and deliver any large molecule. This was after 200 failures of mine, but it showed for the first time you could release them. It's also the first time nucleic acids had been shown to be released. Nucleic acids, for those of you that aren't familiar, are like DNA or RNA. So that's what that graph is.
So a few years later you presented your breakthrough in controlled release systems at the Midland Macromolecular Symposium. Can you talk about what that experience was like and how that shaped you?
Sure. So I practiced this talk for a long time. I was, I think, 27 years old and I gave the talk and I, you know, it's a 20-minute talk and I thought when I was done, and I was a terrible speaker at the time, I was very nervous, but I just, you know, I thought when I was done with the talk, I didn't do that badly because I didn't forget too much what I was going to say. I didn't stammer too much. So I thought when I was done with the talk, you know, and all these people are like a lot of older, very famous chemists and engineers, I thought, you know, and I was so naive, I thought these are going to be nice people, they would want to encourage me, this young guy. I could see the scientists in the room laugh. So at any rate, when I got done, you know, a whole bunch of them come up to me and they said, well, we don't believe anything you just said.
So you have about 1,500 issued and pending patents worldwide. Does that sound about right?
Tell us about the first patent you got. Was that easy?
It's never easy. No, it got rejected five times. So, but I remember there was a guy at Children's Hospital, Al Brazagini. He was head of the tech transfer office there, you know, and I remember one day he came to see me. He said, "Bob, you're costing the hospital so much money." He said, "You should just stop trying to keep filing this. The guy's never going to allow it." And he said, "You should just give up." But, you know, I don't like to give up. And so I started to think, how could we convince the patent examiner to allow it? And I remembered, as I was saying to you, everybody told us this was impossible. It couldn't work. And I wondered maybe someone wrote that down. So in 1982, after getting five years of rejections, I did this. You can do a search. It's called a science citation search and see who wrote about you. And I found some articles that were very helpful saying that this was incredibly surprising that Dr. Folkman and I did that. And we showed that to him, Brazagini, and he showed it to the examiner. And the patent examiner said, gee, he had no idea, but he will allow the patent if I could get written affidavits from the scientists who wrote that article that they really wrote it. So it's actually a great strategy for getting patents. But anyhow, I wrote all five of them and they were nice enough to write me back. They did write it and we did get a very broad patent.
Great. Your humble nature is legendary. People say you see the potential in everyone and it shows. You make everyone feel important. You respect people's time, effort, and interests and you're quick to give credit to others and express appreciation for their individual work and contributions. I never met Shockley, the transistor guy, or Watson, but I hear they weren't the most pleasant to work with. You've had a mega lab, 100 people for years, for decades. I think when you turn 70, and you're a little older now, someone wrote this down: 400 of your trainees are professors, 500 have worked in industry or started companies, 100 or so have worked in government, 48 have been elected to the National Academy of Inventors, 23 National Academy of Medicine, 23 National Academy of Engineering, three National Academy of Sciences, and 40 MIT Tech Review 35 Under 35. How are you able to attract talent? How are you able to develop talent? How do you make this so people weren't eating their young? I mean, you've done something very remarkable. And do you acknowledge that? Do you take ownership of that? And what is it that you've done to facilitate this?
Well, you have people in the audience who probably can answer it better than me, like Dan and others. But I mean, to me, that's why I became a professor and a teacher, was to help people, to teach people. So that is important to me. I mean, I put that first. And so I think that if people know you care about them and also if they feel they're working on things that are really important that can change the world and make it a better place, and I like to think that that's the kinds of things that we have worked on, you know, that the things that you mentioned will happen. I mean, if you treat people well, I think, I mean, and what can I say, why not? I mean, I never met Shockley, but I have met James Watson. You know, I think to me, I would feel awful if somebody had a bad experience in my lab, even if they made a great discovery.
Yeah. So I have a few questions and then we're going to move to the next part of the program. Much of your research was initially dismissed as not real engineering or not real biology. How have the walls between scientific disciplines changed since you began and what work still needs to be done?
Yeah. Well, I think they've changed quite a bit in some ways. You know, when I, though a lot in a lot of ways they haven't, but the simple thing that I usually think about when you mention that is if you went 50 years ago, like I went to Cornell as an undergrad, and it doesn't matter what I'm saying is true for almost every college. You know, there's a building for math, a building for English, a building for chemistry, you know, and I think today, you know, there's buildings like the building I'm in has both biologists and engineers and all engineers, not all seven or eight different, normally there's one for chemical engineering, mechanical, so everybody's together. And I think that, you know, we call that convergence at MIT. I think there's a number of places that are doing that more and more. That doesn't mean that's the only thing you should do, but I think now there's a tremendous amount more interdisciplinary efforts by people.
What helps you be consistently creative and innovative even after decades of cutting-edge work?
Well, it's nice of you to even say that. I guess the way I think about it is, first, it's not just me. We have, like you mentioned, we have a big lab and I think we have an environment that I hope is conducive for people to invent and be creative. And I do encourage that, but I also read a lot and I go to meetings and stuff. You know, you have all these great students and postdocs and fellows coming in. And I also think the Boston area is special that way. You know, the way I think about it is you have MIT, I'm not going to brag too much, but you have MIT, which is, I think, clearly the best engineering place in the world, and you have Harvard, which is probably clearly the best medical place. And you have these people that come back and forth, like fellows, you know, like Dan who's here and Kane who's here and others, and they come to your lab and they mix, the MDs mix with the engineers and, you know, people work together. And I think that when you have so many incredibly bright people, it's not that hard to do what I do.
Yep. How do you decide which high-risk, long-lead projects are worth betting on, especially when resources are finite?
Well, if you think something can make a giant difference and you feel you have the background or the kinds of people that can contribute to it, then I'd probably try it. But they'd be ones that I feel have a high impact. And they're probably, I'm trying to think how best to say this. You know, sometimes you have what I'd call a one-trick pony. We might do something that might affect one disease. Much of what we do are to really create discoveries or inventions or platforms that, if they're successful, could be applied for any disease. I mean, going back to your point with that Nature paper, you know, that was where we delivered large molecules when people thought that wasn't possible. And at that time, if somebody asked me what it would have been useful for, if I was to pick one thing, I probably would have said insulin. That's never come to pass. On the other hand, it's been useful for all kinds of anti-cancer drugs and certainly set the stage for things that Moderna and lots of companies have done with nanoparticles and many, many other applications that I would never have dreamed of in 1974 when I first started doing that. And that's been true for a number of the things like these ideas that I've had with Jay Vacanti about creating new tissues and organs. You just don't know exactly. I'm never smart enough, I don't know if anybody is, to really predict the future, but if you create some broad discovery or invention, you know, whether it's us or somebody else, they'll figure out ways to use it that could be very important, I believe.
What key signals do you look for when deciding which research ideas have commercial spinout potential?
First, the biggest thing I think when people try to start a company in academia is probably starting too early. So what I'd like to have, if you can have everything, is to have a platform technology that can be applied to a lot of different things. I'd also like to have in vivo data, you know, animal data at a minimum. I'd like to have at least one great paper out and I'd like to have a really good patent and then some students or postdocs that really want to work on it. In terms of commercial potential, I think if you have a platform, people, it's not just us that know what the commercial potential is. A lot of times investors and venture capitalists and business people we work with, you know, and clinicians and people brainstorm together to figure out what the best commercial potential is. Most of the time when you look back, the first one that you think of isn't true. It doesn't come to pass. It's rare, I think, that the first one you think has commercial potential is what happens. For example, the first thing was a blue dye, Elan, it was for diseases in the back of the eye. I mean, Moderna, we never had, who would have thought that you're going to have COVID 10 years later? I mean, and on and on. I mean, Momenta, you know, I mean, ends up like myasthenia gravis is one and any autoimmune disease, but none of those you would have thought of in the beginning. And it's a combination of smart people working with you, you know, that help figure those things out and the times and advances that get made.
So Minsky and McCarthy coined the term AI in 1955 when they wrote a grant to the government to do a retreat in Dartmouth. You know, I think Wiener, Institute Professor, you're one of nine, had thought about cybernetics before the term AI. AI has played a big role with AlphaFold, gotten a lot of attention. How do you see AI uniquely surpassing conventional methods today in the life sciences and nano medicine, and what does that look like for the future of the work that you and your group has been doing?
Yeah. Well, first, it's good you pointed out, which a lot of people don't realize, that AI isn't new, right? It's back to, you know, I think most of the population thinks it happened a few years ago.
Yeah. Yeah. It's actually over 80 years old.
Ada Lovelace. I have a book by her.
Yeah. But it goes back over 80 years. But I think the power of computation and advances that people have made, you know, and certainly ChatGPT, that's such a dramatic demonstration for people about what AI can do. You know, it shows people it can be important. At MIT, you know, Rafael Reif when he was president, you know, he established a college of AI and, you know, was a number of years ago. So what can it do? I think the power of AI is when there's an enormous amount of data, good data, it can do a lot. And so, but the misconception that often comes is, well, that it can do anything without the data. And also if the data is not really, what should I say, comparable. Just to give an example, people might think you could go to the literature and predict all kinds of things from clinical trials and things like that that have published. But I think that's doubtful because there's a lot of data that's not going to be there. So a lot of biotech companies have started based on AI and they've fallen flat. And yet it's not surprising to me if you try to say you could go and look at clinical data and make some of these predictions. I mean, there's so much that's not there, right? You may not know what the meals they ate and 5,000 other things. So I think you really need a lot of data. The more data you have, the more good data, the more powerful AI can be. And so I think it will, you know, people are already using it. Regina Barzilay at MIT has been using it for, you know, even giving better predictions for, you know, biopsies like for breast cancer and things like that. We're certainly using it with Dan Anderson on designing better lipid nanoparticles. I mean, there's a tremendous number of things that you can use it for if you have a lot of data. And really the power, I think, is that one could maybe do two things. You could have high-throughput screening, which are biological or analytical techniques that could allow you to get that data. You wouldn't have had that 50 years ago. You could combine that data with AI and I think you'll do very well even from our standpoint. You know, Nick Gados and I and Mike Sefton, we started this company, Transform, 26 years ago to do something very simple. This is in the bio area. So then and still now, most of the drugs that people, or at least maybe half the drugs that people come up with, aren't soluble or the solubility is super low. So what we did is we, Dave Putnam and Hung-Yi Chen in our lab, and then they went to the company, you know, they would do high-throughput screening with solubility. It was pretty easy. You could add different excipients and not just one excipient, you could add combinations and they would do thousands of experiments. And we used, we called it machine learning then, and we could use that and analyze what we did and then we could iterate and iterate and keep doing better and better, you know, and that company ended up doing, you know, very, very well. Johnson & Johnson ultimately acquired it.
What do you see as the next frontier in making medical innovation more accessible worldwide?
Yeah. Well, I think what the Gates Foundation is doing, and we do a lot with them, I mean, they do a lot more, obviously. We're just one little piece, but I think what they're doing is really important. I mean, some of the things that we've worked on with them have to do with better nutrition, you know, which might seem obvious, like why can't you just send vitamin pills, but that doesn't really work. I mean, just to pick an example that we've done in our lab is, you know, something like if you, I'll just pick one country, say you take Nigeria, you know, according to UC Davis, 20,000 kids die a year of vitamin A deficiency. And but one of the things, and you could send them vitamins, but like I say, that won't change anything. But what they do do in Nigeria and some other places in Africa is they have bouillon. So when Bill Gates came to see me, one of the questions they asked is, "Well, could you ever, you know, bouillon you have to boil it, right, for several hours?" He said, "Could you ever put things like vitamin A or iron in a situation where it could be boiled for two hours and nothing would happen, and then when somebody eats it or drinks it, it'll become available?" And, you know, we came up with some ways to do that that I believe will be, that's already approved by the World Health Organization, you know, the FDA equivalents in these countries that I hope will be introduced in a few months. But there's so many things like that. And then we're also working on another thing that makes it difficult is people don't come back for injections for a second vaccine. And we've come up with ways, again, this Anjali Anand in our lab has done this, where you can give one injection and yet you get like 11 boosts with it. It's designing the right kind of nano or microparticles. So that's another thing that's a polymer is facilitating that.
Graduate, he says it's plastic. So maybe...
He said ball bearings.
Yeah. But it could be polymer. It's a combination. If it's an mRNA vaccine, it'll be polymers and lipids. It's still in animal trials, but we've done non-human primates and it's looking promising. But all these things, anytime you try to do any of those things, it takes a lot of work. Other things, to your point, I think are helping, you know, which we're trying to do, myself and Ram Sasisekharan, in different countries and trying to help them start biotechnology industries in a couple different countries in Africa. And I think those are some of the things that I hope will help.
So a few quick props. I'm going to pass this around. This is a 100-year-old MIT yearbook. And I don't know if you know your Star Trek, but Star Trek: The Wrath of Khan.
Happens 250 years from now. What does biology, life sciences, chemistry look like 100, 200 years from now, if you extrapolate where we are and where we're going?
Yeah. Well, I'm sure I won't even be close, but I mean, I'm sure we'll have learned a tremendous amount more.
I think it's in ways that you can't even dream of. I mean, that's also the beauty of science, you know, is doing basic research and making discoveries. I mean, that's generally what, when you mentioned the Nobel Prize, that's usually what it's given for in medicine is discoveries that people make that yield new knowledge. I mean, so when you talked about James Watson, I mean, nobody understood the structure of DNA and he and Francis Crick figured it out. And I think there'll be so many things like that. I think we will understand cells in a different way than we do now. Maybe we'll be able to create cells from scratch and all kinds of things that I think now we just can't even dream of. One of the times I turned older, Edith Mathiowitz, who was one of my postdocs, she did come up with an equation and it had all these things in it which I'll never be able to remember and it went like this and then all of a sudden there was this rise in 1986 and she...
had to do with a neurosurgeon, PhD from...
Neuroscientist. Neuroscientist. Yeah.
Well, she was from Harvard and MIT. So, and then she asked the audience, she said, "Well, why was that? Did it rise so much in 1976?" And she said, "Well, that's when Bob met Laura, who is my wife."
Well, that's a great segue. So I didn't tell you this, but I've deputized four other people to come up here that is kind of like This Is Your Life. And the first is your son. And Sam runs a farm with his wife, I think, in California. And he and I have done a bunch of phone calls and he's really excited to talk to you. And he also brought some images that we've... Oh my God. So Sam, can you come on down?
No, I know. And then we have Dan who's at Children's Hospital and we have Yan who's using your brilliance to help with recycling. And then is Shria here yet? And then Shria who's a professor at Harvard who is connecting the brain to bionics and also doing stuff with pills, which she can explain much better. And they have things that they want to say. So Sam, why don't you come on down and here's the clicker. Yeah. And you're doing great, Bob. You know, he's the most, has the most patents of anyone living, cited the most times, 400,000. Like, he's, this is a legend. And I hope he has bodyguards wherever he goes.
So, Rya, my wife and I, we were sitting over the last few days really thinking about this opportunity of what to ask you and just really thought about some key moments from your life. And we were thinking about what can we ask that maybe people haven't heard, and we thought of a few things.
We thought, you know, first I think we realized that your story really is this hero's journey, you know, this going through all these trials and not knowing how it's going to go. And, you know, at some point you really got to this point where you had succeeded and you had this message to share with people that now I think it's so succinct. It's like you have these clear messages that you've learned, these clear lessons.
And what Rya pointed out too was that when you look at the moments from your life, there were these clear choice points that you had, and we wanted to dig into those choices a little bit, like how you were really able to make them.
And, you know, our intention was to really bring it to moments so that people here can just feel your humanity and just the challenge of the journey too that all of us experience. So we'll start with this picture. What do you know about this picture?
That's me a long time ago.
And if we were to transport ourselves there, what do you think we would find in...
I don't know that you would have found anything terribly surprising. I think I was, I mean, I like to think I was just like a regular little kid. You know, I'd play football with my friends and baseball with my friends. And, you know, I don't think I was a good student. And I don't think I was anything super, but I think I, I don't know if I was like six or whatever there, but I think it was, I mean, I just, I felt I lived in a nice neighborhood with nice kids and it was fun to play.
And one thing I think we see through your journey is you have this persistence, like you're really willing to go for these dreams despite what anyone's telling you. You know, all these rejections and people telling you things. And I'm curious, was there an early moment in life where you were really encouraged to have that persistence, or were you taught to really believe in yourself?
Yeah. I don't, I mean, I really don't think I was. You know, my dad and mom really all the time, they just, I mean, it sounds simple. They said, we just want you to be happy. I mean, they did not push me hard. I mean, they were, you know, my dad was a very smart guy and, you know, and like I said, people said he played math games with me and stuff like that, but I don't think I saw anything like that. I mean, he was a hard worker certainly, but, you know, he ran a liquor store and he'd be there, you know, six days a week and worked long hours. But I mean, that's because he grew up in the Great Depression and got to see a lot of people who were once very wealthy, you know, really get bankrupt and stuff.
Maybe there's something in that 'we just want you to be happy' that's actually able to help you really go after some of these dreams.
I think the nice, I think wanting to be happy, that's, I think that's good. I like that. I think I've probably told, I hope I've told you that.
Definitely. Okay, where are we here?